Interaction between tumor cells and their microenvironment plays a critical role in tumorigenesis and metastasis. Disseminated tumor cells in the blood (circulating tumor cells (CTCs)), particularly CTC clusters, are positively correlated with metastatic potential and poor prognosis. However, the key factors required for tumor cell dissemination and CTC clustering remain elusive. We found that Desmoglein2 (DSG2), a key cell adhesion molecule participated in desmosome mediated intercellular adhesion, and its regulation by hypoxia, a potent microenvironmental factor linked to cancer progression, were critical for breast tumorigenesis, CTC clustering and metastasis.
Introduction
Breast cancer is the most common cancer of women worldwide. With early detection and advance in therapeutic strategies, the 5-year relative survival rate for all stages combined is higher than 90% (according to the SEER database maintained by the U.S. National Cancer Institute).
However, metastasis is now the major cause of breast cancer death (1) as the survival rate for women with metastasized breast cancers remains below 30%. Thus, identification of key factors in breast tumorigenesis and metastasis is important to identify therapeutic targets and strategies to improve prognosis.
Metastasis is a complex process involving tumor cell intrinsic alterations and extrinsic interaction with the microenvironment to select for highly aggressive cancer cells. Hypoxia, a key microenvironmental factor in solid tumors, activates hypoxic signaling in tumor cells to increase cell plasticity by promoting epithelial-to-mesenchymal transition (EMT) to drive the first step of metastasis (2) . High plasticity allows these cancer cells to disseminate from the primary site and intravasate into circulatory or lymphatic system. Most of these circulating tumor cells (CTCs) die in circulation and only a small fraction of CTCs are able to survive and eventually colonize at distant organs (3, 4) . Recent evidence has shown that CTC numbers can be used as an independent predictor for survival in patients with metastatic cancers (5) (6) (7) . With continuous improvement in 5 CTC detection methods, CTC clusters were identified. Evidence has shown that CTCs in the clusters exhibit epithelial/mesenchymal hybrid (partial EMT) phenotype which allows them to move collectively (8) . Collective movement makes these cancer cells to be more apoptosis-resistant and more capable of avoiding immune surveillance and colonizing distant organs. Importantly, the clustering ability of these cancer cells was positively correlated with poor clinical outcome (9) (10) (11) (12) .
However, the factors that drive CTC cluster forming and how these clusters promote metastasis remain elusive.
Cell adhesion proteins play critical roles in intercellular contacts and epithelial tissue dynamics.
Deregulation of cell adhesion molecules contributes to tumor metastasis (13, 14) . Among cell adhesion molecules, desmosomes are of particular interest for cancer biology. Desmosomes form patch-like adhesion structures that mark the intercellular midline and connect to the intermediate filament cytoskeleton to maintain cell-cell adhesion and tissue integrity (15) . The desmosome is a protein complex containing two transmembrane proteins, Desmocollin (DSC1-DSC3) and
Desmoglein (DSG1-DSG4), as well as adaptor proteins, Plakoglobin and Desmoplakin, that bind intermediate filaments (16) . Among the DSGs, DSG2 is the most ubiquitously expressed isoform in many tissues, including mammary, and is a key factor for cell aggregation and oncogenic function in lung and prostate cancers (17) (18) (19) (20) . However, the role of DSG2 in CTC clustering and metastasis 6 remains uncharacterized.
We found that breast cancer patients whose tumors had high DSG2 expression (DSG2-high) had worse prognosis and higher recurrence risk than those with DSG2-low tumors. DSG2 expression enhanced CTC clustering and facilitated metastasis. Tumor growth and colonization were also promoted by DSG2 expression at both the primary site and distant organ. However, suppression of DSG2 mediated by HIF1α under hypoxia was required for intravasation. Once in the circulatory system, the cancer cells were released from hypoxic stress and DSG2 expression was de-repressed.
This reactivation of DSG2 was essential for formation of CTC clusters and colonization of distant organs. Together, these results show that dynamic changes of DSG2 expression are required for breast tumorigenesis, intravasation, CTC clustering and metastasis. Our data also identify regulatory mechanisms underlying DSG2 repression and de-repression during specific stages of breast cancer progression.
Result

High expression of DSG2 in breast cancer is associated with poor prognosis and high recurrence
To identify key factors driving CTC clustering and metastasis, we analyzed a transcriptome dataset for metastatic and non-metastatic breast cancers from the Gene Expression Omnibus (GEO) 7 of the National Center for Biotechnology Information using Gene Set Enrichment Analysis (GSEA).
Forty-six genes associated with metastatic disease were enriched in metastatic breast cancers.
Among these, DSG2 was the most highly expressed (Fig. 1, A and B ). Because formation of CTC clusters (groups of two or more aggregated CTCs) promotes metastasis and because cell-cell interaction is critical for CTC clustering (9), we also analyzed genes associated with cell-cell junctions and found DSG2 as the second highly expressed gene among 56 genes enriched in the metastatic group (SI Appendix, Fig. S1A and B). Overlap of these two gene sets (metastasis and cell-cell junction) identified three genes (SI Appendix, Fig. 1C ). Among these, DSG2 was the gene most highly upregulated in the metastasis and cell-cell junction gene sets enriched in the metastatic breast cancer patients.
We then evaluated clinical correlation of DSG2 expression with prognosis using immunohistochemistry (IHC) analysis of 164 biopsy specimens (Fig. 1C ). Based on the IHC analysis, patients were grouped into "DSG2-high" and "DSG2-low" groups for Kaplan-Meier survival analyses. The disease-free survival was significantly lower in the DSG2-high group (Fig.   1D , p = 0.004). Importantly, DSG2 expression was highly correlated with cancer recurrence (Fig.   1E , p = 0.03). To examine whether high DSG2 expression promoted metastasis, we analyzed a breast cancer cohort from the UCSC Xena public hub (Yau 2010 dataset)(21) and found significantly 8 lower distant metastasis-free survival in DSG2-high breast cancer patients ( Fig. 1F , p = 0.008). The results from these three independent cohorts indicated that DSG2 possesses a metastatic role in breast cancer and can be used as a prognostic marker.
DSG2 expression promotes CTC clustering and facilitates metastasis
To determine DSG2 function in breast cancer progression, we first examined endogenous DSG2 levels in a panel of cell lines (SI Appendix, Fig. 2A ). MDA-MB-231, a model cell line for in vivo metastasis studies due to its high metastatic potential (22) , was found to express the highest level of DSG2. MDA-MB-231 was then used for loss-of-function experiments where DSG2 expression was depleted using a lentiviral-shRNA system (SI Appendix, Fig. 2B ). Depletion of DSG2 on the cell membrane was confirmed by fluorescence activated cell sorting (FACS) (SI Appendix, Fig. 2C ).
To investigate the role of DSG2 in CTC clustering and metastasis, orthotopic xenograft assay was performed by injecting EGFP expressing MDA-MB-231 cells, without (shCtrl) or with (shDSG2) DSG2 depletion, into the 4 th mammary fat-pad of NOD/SCIDγ mice. Nine weeks after mammary fat pad injection, tumor size, CTC counts and lung nodules were evaluated ( Fig. 2A ). Tumors derived from shCtrl cells were bigger ( Fig. 2B ) and these mice had more metastatic nodules in the lungs compared to the mice bearing shDSG2 cell-derived tumors (Fig. 2C ). Moreover, IHC staining confirmed that the cells which colonized and formed nodules in the lungs expressed DSG2 9 ( Fig. 2D ). Using a CTC platform (MiCareo), we observed that not only were there more CTCs detected in the shCtrl group, but also the majority of the CTCs collected from the shCtrl group were clustered (Fig. 2 , E and F). In contrast, shDSG2 had a 5-fold lower prevalence of CTC clusters (278 clusters per gram tumor in the shCtrl group, 59 clusters per gram tumor in the shDSG2 group).
These data indicated that DSG2 facilitates breast cancer metastasis and also promotes CTC clustering.
DSG2 expression promotes metastatic colonization and tumor growth
As colonization is a crucial step to determine whether cancer cells can survive in distant organs (23, 24) , we injected SKBR3 cells, which also had high levels of endogenous DSG2 expression (SI Appendix, Fig. 2A ), with or without DSG2 depletion into mouse tail vein to examine whether DSG2 contributes to colonization ability. Fixation and hematoxylin and eosin (H&E) staining of lung tissue two months after the initial tail vein injection showed that mice injected with DSG2-depleted SKBR3 cells had significantly lower numbers of lung nodules compared to mice injected with control cells (Fig. 3, A and B) . Conversely, DSG2 overexpression in MDA-MB-157 cells, which had low levels of endogenous DSG2 expression (SI Appendix, Fig. 2A ), significantly increased lung colonization by cells ( Fig. 3 , C and D).
In addition, DSG2 promoted tumor growth at the primary site. DSG2 depletion led to significant reduction of colony forming efficiency in soft agar colony forming (SACF) assays ( Fig.   3E ). Conversely, DSG2 overexpression in MDA-MB-157 and MDA-MB-468 cells, which had low endogenous DSG2 levels (SI Appendix, Fig. 2 , A-C), resulted in higher colony numbers ( Fig. 3F ).
Consistent with the tumorigenic role of DSG2 in promoting colony formation, orthotopic xenografts showed that tumors derived from DSG2-depleted cancer cells were significantly smaller than the control while cells overexpressing DSG2 formed significantly larger tumors ( DSG2 has been reported to participate in cell adhesion through its interaction with another desmosome component, DSC2, and to activate EGFR signaling to promote tumor growth (20, 25, 26) . Since not every DSG2-expressing cell line expressed DSC2 or EGFR (SI Appendix, Fig. 3A ), we sought to identify other DSG2-interacting proteins contributing to DSG2-mediated tumorigenesis and colonization. Immunoprecipitation followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) found β-Actin (ACTB) as one of the top candidates among putative DSG2-interactors identified (SI Appendix, Fig. 3B ). DSG2-ACTB interaction was confirmed by Co-IP (SI Appendix, Fig. 3C ). DSG2 interaction with ACTB may be mediated by Plakoglobin (γ -catenin) or Plakophilin, members of the Armadillo protein family that bind DSG2 and the actin cytoskeleton (15, 27) . Importantly, while β-Actin protein level was slightly reduced in DSG2-depleted cells, it was strongly elevated upon DSG2 overexpression (SI Appendix, Fig. 3D ).
This result was consistent with DSG2 promotion of metastasis as increase in β-Actin expression has been particularly implicated in metastatic cancers (28) (29) (30) .
Moreover, dynamic assembly and disassembly of microfilaments (filamentous (F)-Actin) from G-actin monomers is generally important in cell integrity and control of mobility (31) and specifically important for the establishment of a circumferential F-actin belt parallel to the cell-cell contact area (32) . Such microfilament structure is regulated by RhoA GTPase to control membrane rigidity and prevent anchorage detachment (33, 34) . We found that RhoA activity was decreased upon DSG2 suppression but increased when DSG2 was ectopically expressed (SI Appendix, Fig. 3E ).
This result was consistent with the observation that Rho GTPases participated in desmosomal cadherin-mediated cell adhesion (35) . We also observed a dramatic decrease in F-Actin (visualized using phalloidin) in DSG2-depleted cells (SI Appendix, Fig. 3F ). Conversely, ectopic expression of DSG2 significantly increased F-actin (SI Appendix, Fig. 3G ). Together, these data suggested that DSG2 promotion of anchorage independent growth and CTC clustering may be mediated, at least in part, by β-actin-controlled cell junction integrity and remodeling.
DSG2 expression inhibits cell invasion, migration and intravasation by decreasing EMT genes
Initiation of cancer metastasis, including invasion, migration and intravasation, relies heavily on tumor cell dissemination (1, 36). Since DSG2 expression increased CTC clustering and tumor growth in the mammary fat pad and also promoted colonization in the lung, we next evaluated its role in dissemination. Seemingly in contrast to its tumorigenic role, DSG2 knockdown in MDA-MB-231 cells significantly increased migration ability ( Fig. 4A ) and DSG2 overexpression in MDA-MB-157 cells inhibited migration ( Fig. 4B) . Similarly, depletion of DSG2 increased cell invasion; whereas overexpression of DSG2 inhibited this ability (Fig. 4 , C and D). Consistent with these observations, DSG2 depletion resulted in an upregulation of EMT genes, including SNAIL, SLUG and VIMENTIN, all of which are critical for cancer cell mobility and dissemination (37, 38) .
Conversely, DSG2 overexpression downregulated these genes (SI Appendix, Fig. 4 ). Together these findings indicated that suppression of DSG2 facilitates invasion and migration not only by disruption of cell-cell adhesion but also by upregulation of EMT genes.
We next examined whether DSG2 depletion promotes intravasation in vivo using orthotopic xenograft model. Five weeks after injection of EGFP expressing MDA-MB-231 cells transduced with shDSG2 or shCtrl, FACS detection of CTCs in blood samples found higher CTC numbers in mice xenografted with DSG2-depleted cells than in the control (Fig. 4E) . These results demonstrated that DSG2 suppression promotes cell migration, invasion and intravasation into the 13 circulatory system. Intriguingly, blood samples collected 8-weeks after injection of shCtrl MDA-MB-231 contained CTC numbers just as high as those mice injected with DSG2-depleted cells (Fig. 4F ). This result indicated that from 5-8 weeks after injection, tumors derived from the shCtrl MDA-MB-231 cells underwent some alteration that increased intravasation ability. Interestingly, at 8 weeks after injection, tumors derived from the shCtrl MDA-MB-231 cells had high DSG2 in the tumor boundary but low DSG2 in the tumor central region (Fig. 4G ). This DSG2 expression pattern was opposite to intra-tumor hypoxia gradient (high in the center but low in the boundary) (39) and indicated that DSG2 expression may be downregulated by hypoxia. Consistent with this hypothesis, we found a negative correlation between expression of DSG2 and CAIX, a hypoxic stress marker, in tumor sections from the mouse xenograft model (Fig. 4H ). This inverse correlation was also observed in clinical specimens where it was observed that regions with high DSG2 expression had low CAIX expression and vice versa (Fig. 4I ).
Hypoxia-induced HIF1α suppresses DSG2 expression
Hypoxia plays a critical role in metastasis (2) but it is not known whether hypoxia affects DSG2 suppression during tumor progression. Consistent with the pattern of DSG2 expression in tumor specimens, breast cancer cells subjected to hypoxic stress had decreased DSG2 gene expression and 14 protein level (Fig. 5, A and B) . Similarly, DSG2 expression decreased in cells treated with different doses or durations of the hypoxia-mimetic agent CoCl2 (SI Appendix, Fig. 5, A and B) . Since
HIF1α is a critical mediator of hypoxia-associated cancer progression (40), we determined the effect of HIF1α on DSG2 expression. Transient transfection of a non-degradable HIF1α (P564A) in HEK-293T cells resulted in downregulation of DSG2 (Fig. 5C ). Importantly, depletion of HIF1α in HEK-293T treated with CoCl2 abolished hypoxia-induced DSG2 suppression (Fig. 5D ). These results indicated that HIF1α is responsible for DSG2 suppression under hypoxic stress.
To further elucidate whether HIF1α directly suppressed DSG2 transcription, we used Integrated Motif Activity Response Analysis (ISMAR) (41) to identify putative HIF1α binding sites and found that mutation of one of these sites (-946 to -943) abolished HIF1α inhibition of DSG2 expression ( Fig. 5E ). Chromatin-immunoprecipitation (ChIP) further confirmed that hypoxia-induced HIF1α bound to this region ( Fig. 5F and SI Appendix, Fig. 5C ). To understand how HIF1α carried out this transcriptional suppression, we performed Co-IP assays and found HIF1α interaction with polycomb repressive complex 2 components, EZH2 and SUZ12, but not HDAC1 and HDAC2, in breast cancer cells under hypoxia (SI Appendix, Fig. 5 , D and E). Upon hypoxic stress, these co-repressors associated with the HIF1α-binding region on the DSG2 promoter leading to an increase in H3K27-trimethylation (H3K27me3) indicative of heterochromatin formation (Fig. 5G ). Together, these results indicated that HIF1α recruits PRC2 complex to the DSG2 promoter to suppress its transcription under hypoxic stress.
Since DSG2 is critical for distant organ colonization and expressed in metastatic nodules (Fig. 2 and Fig. 3 ), DSG2 suppression that occurs in hypoxic conditions must be released before colonization can occur. Consistent with this idea, de-repression of DSG2 expression was observed after breast cancer cells were released from hypoxia in vitro (Fig. 5H ). To confirm that this reactivation is important in vivo, we injected EGFP expressing MDA-MB-231 cells into mammary fat pads and evaluated DSG2 expression in CTCs after injection. Before injection, nearly all cells expressed DSG2 (98.6%, Fig. 5I ). At nine weeks after injection, more than 90% of CTCs disseminated from the primary tumor site expressed DSG2 while 9% had low/non-detectable DSG2, possibly indicating that they had just been released from the primary tumor and undergone intravasation (Fig. 5I ). These data indicated that hypoxia-mediated DSG2 suppression followed by de-repression of DSG2 when hypoxic stress is released in the circulatory system is required for DSG2-promoted breast cancer metastasis.
Discussion
Our study demonstrated that dynamic changes in DSG2 expression are important for breast tumorigenesis and malignancy (Fig. 6 ). High DSG2 expression facilitated breast tumor growth in mammary tissue, CTC clustering in blood and colonization in lung. However, downregulation of DSG2 was critical for intravasation. In addition to the clinical implications of these results, we also mark out clear avenues to further establish the molecular basis of DSG2 function in cancer progression. Unlike in colon cancer where DSG2 interacted with EGFR and AKT/β-catenin signaling to promote cancer cell proliferation (26, 42) , DSG2 promoted breast tumor growth by elevating anchorage-independent growth ability. This may be associated with Rho A/β-actin controlled cell junction formation. Interestingly, the actin cytoskeleton has previously been implicated in CTC stabilization and dissemination (43) . Our results further demonstrated that DSG2 overexpression could promote tumorigenesis in MDA-MB-157 and SKBR3 cells even though MDA-MB-157 cells do not express DSC2, and neither MDA-MB-157 nor SKBR3 express EGFR (SI Appendix, Fig. 3A) . Thus, there are likely to be other, yet unidentified, DSG2 interacting transmembrane proteins critical for DSG2-mediated tumorigenic activity. Furthermore, the correlation between DSG2 expression and β-Actin protein level as well as EMT gene expression is also intriguing. In normal epithelial cells, cytoplasmic β-Actin and γ-Actin, are both expressed (44); however, β-Actin specifically controls the steady-state adhesion junction integrity, is required for apico-basal cell polarity and, cooperates with γ-Actin to from three-dimensional epithelial cysts (45) .
All of these functions are consistent with DSG2-mediated changes in adhesion during tumorigenesis and colonization. Whether high DSG2 expression affects microfilament stability via DSG2-associated actin binding proteins and how perturbed DSG2 expression dysregulates β-Actin and EMT gene expression remain to be elucidated.
Consistent with our observations that DSG2 expression promoted CTC clustering (Fig. 2) , Plakoglobin (γ-catenin), a member of the Armadillo family proteins that binds DSG2 and the actin cytoskeleton, has also been shown to contribute to CTC cluster formation and cancer metastasis (9, 46) . Moreover, CTCs that can survive in the circulatory system and colonize in distant organs are thought to be cancer stem-like cells and are highly correlated with metastasis (47, 48) . Consistent with this notion, DSG2 has recently been identified as a marker for pluripotent stem cells (PSCs) and is critical for PSC self-renewal and reprogramming (49) . How DSG2 may contribute to cancer stemness is another topic of interest for further experiments.
Our clinical data and animal models clearly demonstrated that DSG2 can be used as a prognostic marker for breast cancer. Interestingly, DSG2 expression is also associated with poor prognosis in other cancers including cervical, head and neck and lung cancers (SI Appendix, Fig. 6 ).
This suggests a widespread role of DSG2 in cancer malignancy. As a transmembrane protein, DSG2 may be a drugable target. However, the strategy has to be carefully designed. Using a monoclonal DSG2 specific antibody to target the DSG2 to inhibit anchorage independent growth DSG2 suppression allows EMT, invasion and intravasation to occur. In circulatory system, hypoxic stress is released and DSG2 expression is reactivated which allows CTC clustering in blood and colonization in lung. C   GSM120655  GSM120656  GSM120662  GSM120668  GSM120671  GSM120679  GSM120687  GSM120661  GSM120664  GSM120667  GSM120674  GSM120676  GSM120689  GSM120691  GSM120670  GSM120693  GSM120694  GSM120695  GSM120696  GSM120697  GSM120703  GSM120673   DSG2 
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